

AMENDMENTS TO THE SPECIFICATION

Please add the following paragraph to the beginning of the specification.

This application is a U.S. National Stage filing of International Application No. PCT/IB2003/005181, filed September 19, 2003, which claims priority to U.S. Provisional Application Number 60/412,624, filed September 20, 2002. All of the foregoing applications are hereby incorporated herein by reference in their entirety.

Please replace paragraph [0060] of the published application (U.S. Publication No. 20060121033) with the following marked up paragraph:

[0060] Preferably, a monoclonal antibody against the C-type lectin(s) on dendritic or macrophage cells is used, more specifically against the peptide with the amino acid sequence shown in/encoded by SEQ ID NOs:2 and 1 or an antigenic part thereof. Although two monoclonal antibodies, herein referred to as AZN-D1 and AZN-D2, are illustrated herein, those skilled in the art can generate functional monoclonal antibodies with comparable specificity for C-type lectins. Hybridomas that produce the abovementioned monoclonal antibodies AZN-D1 and AZN-D2 of the invention were deposited on Apr. 8, 1999 with the European Collection of Cell Cultures (ECACC), Centre for Applied Microbiology and Research, Porton Down, Salisbury, Wiltshire SP4 0JG, United Kingdom, under ~~provisional~~ ECACC accession numbers 99040818 and 99040819, respectively.